MAP2K7 and melanoma: The AXLhigh de-differentiation melanoma program has been linked to melanoma invasiveness34, BRAF and MEK inhibitor resistance39–41 and is associated with intrinsic resistance to PD-1 inhibitor monotherapy in melanoma patients17.